» Articles » PMID: 17962810

Sporadic Childhood Hepatoblastomas Show Activation of Beta-catenin, Mismatch Repair Defects and P53 Mutations

Overview
Journal Mod Pathol
Specialty Pathology
Date 2007 Oct 27
PMID 17962810
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatoblastoma, a rare embryonic tumor that may arise sporadically or in the context of hereditary syndromes (familial adenomatous polyposis and Beckwith-Wiedemann's) is the most frequent liver cancer of childhood. Deregulation of the APC/beta-catenin pathway occurs in a consistent fraction of hepatoblastomas, with mutations in the APC and beta-catenin genes implicated in familial adenomatous polyposis-associated and sporadic hepatoblastomas, respectively. Alterations in other cancer-related molecular pathways have not been reported. We investigated a series of 21 sporadic paraffin-embedded hepatoblastoma cases for mutations in the p53 (exons 5-8) and beta-catenin (exon 3) genes, loss of heterozygosity at APC, microsatellite instability and immunohistochemical expression of beta-catenin and of the two main mismatch repair proteins, MLH1 and MSH2. No loss of heterozygosity at APC was detected. We found mutations in beta-catenin and p53 in 4/21 (19%) and 5/21 (24%) cases respectively, beta-catenin protein accumulation in 14/21 cases (67%), microsatellite instability in 17/21 cases (81%), of which eight resulted positive for high-level of microsatellite instability (in four cases associated with loss of MLH1/MSH2 immunostaining). No correlations between involved molecular pathway(s) and hepatoblastoma histotype(s) emerged. This study confirms that beta-catenin deregulation is involved in sporadic hepatoblastoma and also suggests that mismatch repair defects and p53 mutations contribute to this rare liver cancer. Sporadic hepatoblastoma appears to be molecularly and phenotypically heterogeneous and may reflect different pathways of liver carcinogenesis.

Citing Articles

Pediatric cancer predisposition syndromes involving non-central nervous system solid pediatric tumors: a review on their manifestations with a focus on histopathology.

Schurink B, Reyes-Mugica M, de Krijger R Virchows Arch. 2025; 486(1):3-21.

PMID: 39847050 PMC: 11782299. DOI: 10.1007/s00428-025-04029-1.


Current and Emerging Molecular Markers of Liver Diseases: A Pathogenic Perspective.

Liang Y, Guo G, Zhang L Gene Expr. 2024; 21(1):9-19.

PMID: 38911667 PMC: 11192043. DOI: 10.14218/gejlr.2022.00010.


Unraveling the Genetic Architecture of Hepatoblastoma Risk: Birth Defects and Increased Burden of Germline Damaging Variants in Gastrointestinal/Renal Cancer Predisposition and DNA Repair Genes.

Aguiar T, Teixeira A, Scliar M, Sobral de Barros J, Lemes R, Souza S Front Genet. 2022; 13:858396.

PMID: 35495172 PMC: 9039399. DOI: 10.3389/fgene.2022.858396.


Identification of Ten Core Hub Genes as Potential Biomarkers and Treatment Target for Hepatoblastoma.

Sun R, Li S, Zhao K, Diao M, Li L Front Oncol. 2021; 11:591507.

PMID: 33868991 PMC: 8047669. DOI: 10.3389/fonc.2021.591507.


Insights Into the Somatic Mutation Burden of Hepatoblastomas From Brazilian Patients.

Aguiar T, Rivas M, Costa S, Maschietto M, Rodrigues T, Sobral de Barros J Front Oncol. 2020; 10:556.

PMID: 32432034 PMC: 7214543. DOI: 10.3389/fonc.2020.00556.